DNA RNA and Cells

19 Jun 2018 Fortress Biotech Announces Publication of Phase 1 Data on CNDO-109-Activated Allogeneic Natural Killer Cells in Acute Myeloid Leukemia in Biology of Blood and Marrow Transplantation
19 Jun 2018 Sarepta Therapeutics Announces that at its First R&D Day, Jerry Mendell, M.D. Presented Positive Preliminary Results from the First Three Children Dosed in the Phase 1/2a Gene Therapy Micro-dystrophin Trial to Treat Patients with Duchenne Muscular Dystrop
19 Jun 2018 Solid Biosciences Announces FDA Removes Clinical Hold on SGT-001
19 Jun 2018 Ziopharm Oncology Reports on Status of Investigational New Drug Application for Phase 1 Trial to Evaluate CD19-targeted CAR T Therapy
17 Jun 2018 Novartis JULIET trial of Kymriah demonstrates more than one-year durability of responses in adults with relapsed or refractory DLBCL
15 Jun 2018 Atara Biotherapeutics’ Tab-cel™ Achieves Positive Long-Term Outcomes in Phase 2 Studies of Patients with Epstein-Barr Virus Associated Post-Transplant Lymphomas
15 Jun 2018 Nohla Announces Presentation of Dilanubicel (NLA101) Data at EHA Annual Meeting Showcasing Excellent Long-term Survival Outcomes
13 Jun 2018 Herantis Pharma announces initiation of Phase 2 study for Lymfactin® gene therapy in secondary lymphedema
12 Jun 2018 Synlogic Presents Preclinical Data from Synthetic BioticTM Medicine, SYNB1618, for the Treatment of Phenylketonuria
12 Jun 2018 Pluristem Reports Positive Top-Line Results from Its Multinational Phase II Intermittent Claudication Study
12 Jun 2018 Asterias Biotherapeutics Announces First Patient Dosed in First-in-Human Clinical Study of Immunotherapy AST-VAC2 in Non-Small Cell Lung Cancer
12 Jun 2018 ProQR Receives up to $5 Million in Partnership with EB Research Partnership and EB Medical Research Foundation to Develop QR-313 for the Treatment of Dystrophic Epidermolysis Bullosa
12 Jun 2018 Idera Pharmaceuticals Reports Results from Phase 2 Trial of IMO-8400 in Dermatomyositis
11 Jun 2018 Targovax Strengthens Focus on ONCOS Oncolytic Virus Development Program
11 Jun 2018 Cellenkos™, Inc. Announces FDA Clearance of Investigational New Drug Application for CK0801 for Bone Marrow Failure Syndromes
08 Jun 2018 Celixir announces US FDA approval of the IND application for cell therapy HeartcelTM
07 Jun 2018 4D pharma plc Enters Into Clinical Collaboration Agreement With MSD Investigating the Combination of KEYTRUDA® (pembrolizumab) and MRx0518 in Patients With Solid Tumours
06 Jun 2018 Oxford BioMedica and Axovant Sciences enter into a $842.5 Million Exclusive Worldwide Licence Agreement for OXB-102 for the Treatment of Parkinson’s Disease
05 Jun 2018 FDA Grants Cellectis IND Approval for UCART22 in B-ALL
04 Jun 2018 Kite Announces New Data Analyses for CAR T Therapy in Patients with Blood Cancers at the 2018 American Society of Clinical Oncology Meeting
04 Jun 2018 Kite Announces Initial Results From a Phase 1 Study of T Cell Receptor (TCR) Cell Therapy in HPV-16-Positive Solid Tumors
04 Jun 2018 Cellerant Therapeutics, Inc. CLT-008 Phase 2 Results Show Significant Reduction in Infections and Days in Hospital in Severely Neutropenic AML Patients
04 Jun 2018 Transgene’s Lead Oncolytic Virus Pexa-Vec Triggers Strong Anti-Tumor Immunity after Intravenous Administration
04 Jun 2018 Eureka Therapeutics Announces Positive Preliminary Results of ET190L1-ARTEMISTM T-cell China Proof-of-Concept Human Clinical Study in Relapsed and Refractory (r/r) B-cell Lymphoma at ASCO Annual Meeting
04 Jun 2018 Sangamo Announces U.K. Authorization Of Clinical Trials Evaluating Zinc Finger Nuclease In Vivo Genome Editing Treatments SB-318 For MPS I And SB-913 For MPS II

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up